Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01456065
Other study ID # LRT-I-L01 Ovar
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received September 14, 2011
Last updated February 28, 2013
Start date September 2010
Est. completion date April 2013

Study information

Verified date February 2013
Source Life Research Technologies GmbH
Contact n/a
Is FDA regulated No
Health authority Austria: Agency for Health and Food Safety
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic Cells) [Procure®] in patients with advanced ovarian cancer, enrolled into the study within twelve weeks after completing primary therapy.


Description:

This is an uncontrolled, randomized, parallel-group, open-label phase I trial in patients with advanced epithelial ovarian cancer. Patients were randomized into treatment group A with weekly administration versus treatment group B with bi-weekly administration.

Patients in both treatment groups received a maximum of eight injections administered one by one once a week for eight times for treatment group A and once in a fortnight for eight times for treatment group B.

The treatment was completed within seven weeks for Arm A and within 14 weeks for Arm B. Independently of the treatment arm they had been assigned to, all the patients were followed for a period covering a total of 12 or 19 weeks or until disease progression. Safety parameters (primary objective) and efficacy parameters (secondary objective) were recorded. Upon completion of the treatment, one follow-up visit took place at week 12 (group A, only) or 19 (group B, only).

To protect the patients' safety, the first six patients were treated as described below:

- The first patient was hospitalized and kept under medical observation for 72h after administration of the first and second dose of the investigational product;

- After an observational period of 3 days following the second dose of the first patient, the second and the third patient were administered the first dose of the investigational product, hospitalized and kept under medical observation for 72h. The two patients were treated simultaneously or consecutively;

- After an observational period of 3 days after the second dose to the first three patients, an interim safety report was sent to the Ethics Committee;

- Additionally the next three patients were hospitalized, administered their first dose of the vaccine and kept under medical observation for 72h. The three patients were treated simultaneously or consecutively.

15 evaluable patients (which were randomized to one of the two treatment groups in equal numbers) 5 study sites in Austria and Hungary


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion criteria:

Patients with epithelial ovarian cancer FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) stage III in remission after treatment with surgery (hysterectomy and ovariectomy) and after the first primary chemotherapy (standard treatment e.g. 6-9x Carboplatin/Taxane)

- Age > 18 = 75 years

- Histological confirmed FIGO stage III ovarian epithelial cancer

- Stable disease at screening visit: negative CT and CA-125 within normal range

- Karnofsky status = 70% and/or ECOG (Eastern Cooperative Oncology Group) performance status 0-2

- Life expectancy = 6 months

- Adequate hematological function (WBC (white blood cells) = 3000/µl, hemoglobin = 10.0 g/dL, platelets > 100,000/µl)

- Adequate renal and hepatic function (serum creatinine = 2.0 mg/dL, bilirubin total < 2 mg/dL, PT (INR) = 1.5x institutional upper limit of normal)

- Signed and dated informed consent before the start of any study-specific procedure

- Body weight > 50 kg

Exclusion criteria:

- Surgery, radiation therapy or chemotherapy within eight weeks prior to leukapheresis

- Other biological therapy (Interferons, TNF (Tumor necrosis factors), Interleukins, mABs (Monoclonal antibodies), biological response modifiers) within eight weeks prior to undergo the leukapheresis

- History or presence of systemic autoimmune disease (such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma or multiple sclerosis)

- Participation in other clinical trials or treatments with an investigational drug within four weeks prior to enrollment

- Serious intercurrent chronic or acute illness such as severe asthma or COPD (Chronic Obstructive Pulmonary Disease), cardiac (NYHA (New York Heart Association ) class III or IV) or hepatic disease, or other illness considered to constitute an unwarranted high risk for investigational drug treatment

- History of another malignancy within five years prior to study enrollment, except curatively treated non-melanotic skin cancer or cervical cancer in situ

- Presence of an active acute or chronic infection, including syphilis, HIV or viral hepatitis B and/or C

- Current treatment with corticosteroids (except of local) or other immunosuppressive agents such as azathioprine or cyclosporine A is excluded on the basis of its potential immune suppression. Any systemic steroid therapy must have been discontinued six weeks prior to undergo the leukapheresis

- Patients who have undergone organ transplantation

- Legally incapacitated persons and/or other circumstances, which make it difficult for the subject to understand the nature, meaning and consequences of the clinical study

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Procure
The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
Procure
The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.

Locations

Country Name City State
Austria Hospital Landeskrankenhaus Innsbruck Innsbruck
Austria Hospital Korneuburg Korneuburg
Austria Hospital Barmherzigen Schwestern Linz
Hungary National Oncology Institute Budapest
Hungary Semelweis University Budapest

Sponsors (1)

Lead Sponsor Collaborator
Life Research Technologies GmbH

Countries where clinical trial is conducted

Austria,  Hungary, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events and clinical relevant deviations from Laboratory parameters from first treatment until up to 12 to 19 weeks Yes
Secondary Number of circulating tumor cells in peripheral blood Circulating tumor cells (CTCs) will be quantified prior vaccination and follow up. CTCs will be enriched from peripheral blood and characterized by specific biomarkers. Quantitation of CTCs will provide information about the stage of a malignancy, onset of disease progression and response of therapy. from first treatment till up to 12 to 19 weeks No
Secondary Immune monitoring - Number of autologous dendritic cells loaded with tumor specific antigens Immune monitoring will be done prior vaccination and during treatment. The immune reaction of the patients will be surveyed by determination of the frequency of specific markers for T-Cells, activated T-cells,B-cells,NK (Natural Killer)-cells, NKT (Natural Killer T)-cells.Quantification of these cells will be done by multicolour FACS (Florescence activated cell sorting). This method will be applied to determine the effects of dendritic cell treatment on the patients immune system. from first treatment until treatment visit 7 up to 12 weeks No
Secondary time to progression (CA (Cancer Antigen)-125 and CT (Computer tomography) from first treatment until up to 12 to 19 weeks No
Secondary Overall survival from first treatment until up to 96 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02096783 - Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer N/A
Recruiting NCT06404671 - Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Not yet recruiting NCT03220932 - Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer Phase 3
Not yet recruiting NCT05937620 - Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer N/A
Completed NCT02107937 - Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma Phase 2
Completed NCT02039388 - Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma N/A
Completed NCT02107950 - Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma Phase 2
Completed NCT01806350 - Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors N/A
Recruiting NCT03349463 - Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Phase 4
Completed NCT04823871 - Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing N/A
Completed NCT02518256 - Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity N/A
Active, not recruiting NCT03078400 - Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer Phase 1
Completed NCT02489903 - RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Phase 2
Not yet recruiting NCT02435186 - p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer Phase 2
Recruiting NCT04029909 - A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer Phase 1
Recruiting NCT05498597 - AMT-151 in Patients With Selected Advanced Solid Tumours Phase 1
Suspended NCT02742428 - Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer N/A
Active, not recruiting NCT02981901 - Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
Completed NCT02062697 - Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes. N/A